Objective The aims of this study were to investigate the kinetic changes of serum, virological,
and immunological markers during entecavir (ETV) antiviral therapy and to explore whether …

The aim of this study was to determine the correlation between dynamic changes in serum
cytokine/chemokine expression levels in response to entecavir (ETV) treatment and HBV e …

Background Hepatitis B e antigen (HBeAg) status is associated with clinical outcomes, and
seroconversion of HBeAg is one of the treatment goals. In this study, we determined the …

B1 cell-derived natural antibodies are non-specific polyreactive antibodies and can activate
the complement pathway leading to lysis of enveloped virus particles before activation of the …

Background: Entecavir (ETV) is an antiviral medication effective in suppressing hepatitis B
virus (HBV) replication and improving liver function. However, the relationship between …

Background and aims To evaluate the antiviral response of hepatitis B e antigen (HBeAg)-
positive chronic hepatitis B (CHB) patients who had baseline high viral load (HVL), defined …

Objective This study aimed at evaluating the efficacy and safety of a combination treatment
of entecavir and Peginterferon alpha-2a for HBeAg positive chronic hepatitis B patients with …

Objective To investigate the efficacy and safety of peginterferon alfa-2a (Peg-IFNa-2a)
therapy for treating chronic hepatitis B (CHB) in patients who failed to achieve a satisfactory …

Background Serum quantitative hepatitis B surface antigen (HBsAg) levels may be an
important predictor of hepatitis B e antigen (HBeAg) seroconversion (SC) in HBeAg-positive …

Background & Aims Serum HBsAg levels might represent an important predictor of
sustained off-treatment response in HBeAg-negative chronic hepatitis B (CHB). We …